Hospitals and Clinics Maintain Strong End-User Positioning
Hospitals remain a dominant end-user segment within the Blood Screening Market due to their volume of transfusions, organ transplants, and centralized labs. MRFR notes that this site of care captured the largest revenue share in recent years, buoyed by integration of Advanced Patient Blood Management protocols and increasing public safety obligations. The market is expected to grow from USD 3.40 billion in 2024 to USD 5.60 billion by 2032. As hospitals modernize, buying behavior shifts toward full-service packages—screening instruments, reagents, software, and maintenance contracts—supporting sustained revenue growth. Clinics and standalone diagnostic labs are also ramping up, especially as point-of-care needs rise in rural or decentralized settings. Together, these end-user segments form the backbone of market resilience and expanded reach.